Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives

Bibliography

• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
   PubMed Web of Science ®Google Scholar
• Sangro B, D'Avola D, Inarrairaegui M, Prieto J. Transarterial therapies for hepatocellular carcinoma. Expert Opin Pharmacother 2011;12:1057-73
   PubMed Web of Science ®Google Scholar
• Peck-Radosavljevic M, Greten TF, Lammer J, et al. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2010;22:391-8
   PubMed Web of Science ®Google Scholar
• Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006;25:3866-84
   PubMed Web of Science ®Google Scholar
• Zeestraten EC, Speetjens FM, Welters MJ, et al. Addition of interferon-alpha to the p53-SLP(R) vaccine results in increased production of interferon-gamma in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int J Cancer 2013;132:1581-91
   PubMed Web of Science ®Google Scholar
• Chen LT, Chen MF, Li LA, et al. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg 2012;255:8-17
   PubMed Web of Science ®Google Scholar
• Bruix J, Poynard T, Colombo M, et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 2011;140:1990-9
   PubMed Web of Science ®Google Scholar
• Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-8
   PubMed Web of Science ®Google Scholar
• Lai CL, Lau JY, Wu PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993;17:389-94
   PubMed Web of Science ®Google Scholar
• Kjaer M. Combining 5-fluorouracil with interferon-alpha in the treatment of advanced colorectal cancer: optimism followed by disappointment. Anticancer Drugs 1996;7:35-42
   PubMed Web of Science ®Google Scholar
• Joffe JK, Perren TJ, Bradley C, et al. A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. Br J Cancer 1997;75:423-6
   PubMed Web of Science ®Google Scholar
• Pavlidis N, Nicolaides C, Athanassiadis A, et al. Phase II study of 5-fluorouracil and interferon-gamma in patients with metastatic colorectal cancer. A hellenic cooperative oncology group study. Oncology 1996;53:159-62
   PubMed Web of Science ®Google Scholar
• Ajani JA, Rios AA, Ende K, et al. Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. J Biol Response Mod 1989;8:140-6
   PubMedGoogle Scholar
• Hersh EM, Metch BS, Muggia FM, et al. Phase. II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the southwest oncology group experience. J Immunother 1991;10:426-31
   PubMed Web of Science ®Google Scholar
• Whitehead RP, Fleming T, Macdonald JS, et al. A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a southwest oncology group study. J Biol Response Mod 1990;9:588-91
   PubMedGoogle Scholar
• Li M, Xu T, Zhang Z, et al. Phase II multicenter, randomized, double-blind study of recombinant mutated human tumor necrosis factor-alpha in combination with chemotherapies in cancer patients. Cancer Sci 2012;103:288-95
   PubMed Web of Science ®Google Scholar
• Skog AL, Wersall P, Ragnhammar P, et al. Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression. Cancer Immunol Immunother 2002;51:255-62
   PubMed Web of Science ®Google Scholar
• Hernandez-Alcoceba R, Sangro B, Prieto J. Gene therapy of liver cancer. Ann Hepatol 2007;6:5-14
   PubMed Web of Science ®Google Scholar
• Kaufmann JK, Nettelbeck DM. Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond. Trends Mol Med 2012;18:365-76
   PubMed Web of Science ®Google Scholar
• Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem Rev 2009;109:259-302
   PubMed Web of Science ®Google Scholar
• Delalande A, Postema M, Mignet N, et al. Ultrasound and microbubble-assisted gene delivery: recent advances and ongoing challenges. Ther Deliv 2012;3:1199-215
   PubMedGoogle Scholar
• Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012;30:658-70
   PubMed Web of Science ®Google Scholar
• Eager RM, Nemunaitis J. Clinical development directions in oncolytic viral therapy. Cancer Gene Ther 2011;18:305-17
   PubMed Web of Science ®Google Scholar
• Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 2008;1785:217-31
   PubMed Web of Science ®Google Scholar
• Tong AW, Senzer N, Cerullo V, et al. Oncolytic viruses for induction of anti-tumor immunity. Curr Pharm Biotechnol 2012;13:1750-60
   PubMed Web of Science ®Google Scholar
• Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997;3:409-17
   PubMed Web of Science ®Google Scholar
• Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997;90:2541-8
   PubMed Web of Science ®Google Scholar
• Sangro B, Mazzolini G, Ruiz J, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004;22:1389-97
   PubMed Web of Science ®Google Scholar
• Citrin D, Camphausen K, Wood BJ, et al. A pilot feasibility study of TNferade biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer. Oncology 2010;79:382-8
   PubMed Web of Science ®Google Scholar
• Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008;9:533-42
   PubMed Web of Science ®Google Scholar
• Rubin J, Galanis E, Pitot HC, et al. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther 1997;4:419-25
   PubMed Web of Science ®Google Scholar
• Palmer DH, Mautner V, Mirza D, et al. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol 2004;22:1546-52
   PubMed Web of Science ®Google Scholar
• Atencio IA, Grace M, Bordens R, et al. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a phase 1 colorectal cancer trial. Cancer Gene Ther 2006;13:169-81
   PubMed Web of Science ®Google Scholar
• Penuelas I, Boan J, Marti-Climent JM, et al. Positron emission tomography and gene therapy: basic concepts and experimental approaches for in vivo gene expression imaging. Mol Imaging Biol 2004;6:225-38
   PubMed Web of Science ®Google Scholar
• Penuelas I, Mazzolini G, Boan JF, et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 2005;128:1787-95
   PubMed Web of Science ®Google Scholar
• Kondo H, Hazama S, Kawaoka T, et al. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res 2008;28:379-87
   PubMed Web of Science ®Google Scholar
• Mazzolini G, Alfaro C, Sangro B, et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 2005;23:999-1010
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Finke S, Trojaneck B, et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999;81:1009-16
   PubMed Web of Science ®Google Scholar
• Sobol RE, Shawler DL, Carson C, et al. Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a phase I study. Clin Cancer Res 1999;5:2359-65
   PubMed Web of Science ®Google Scholar
• Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145-56
   PubMed Web of Science ®Google Scholar
• Laheru D, Lutz E, Burke J, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008;14:1455-63
   PubMed Web of Science ®Google Scholar
• Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Ann Surg 2011;253:328-35
   PubMed Web of Science ®Google Scholar
• Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002;62:6070-9
   PubMed Web of Science ®Google Scholar
• Liu TC, Hwang T, Park BH, et al. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008;16:1637-42
   PubMed Web of Science ®Google Scholar
• Bunuales M, Garcia-Aragoncillo E, Casado R, et al. Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and syrian hamster models of cancer. Hum Gene Ther 2012;23:1258-68
   PubMed Web of Science ®Google Scholar
• Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009;9:64-71
   PubMed Web of Science ®Google Scholar
• Kim JH, Oh JY, Park BH, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 2006;14:361-70
   PubMed Web of Science ®Google Scholar
• Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011;477:99-102
   PubMed Web of Science ®Google Scholar
• Alba R, Bosch A, Chillon M. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 2005;12(Suppl 1):S18-27
   PubMed Web of Science ®Google Scholar
• Morral N, O'Neal W, Rice K, et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999;96:12816-21
   PubMed Web of Science ®Google Scholar
• Gonzalez-Aparicio M, Alzuguren P, Mauleon I, et al. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut 2011;60:341-9
   PubMed Web of Science ®Google Scholar
• Vanrell L, Di Scala M, Blanco L, et al. Development of a liver-specific tet-on inducible system for AAV vectors and its application in the treatment of liver cancer. Mol Ther 2011;19:1245-53
   PubMed Web of Science ®Google Scholar
• Zabala M, Wang L, Hernandez-Alcoceba R, et al. Optimization of the tet-on system to regulate interleukin 12 expression in the liver for the treatment of hepatic tumors. Cancer Res 2004;64:2799-804
   PubMed Web of Science ®Google Scholar
• Zabala M, Lasarte JJ, Perret C, et al. Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J Hepatol 2007;47:807-15
   PubMed Web of Science ®Google Scholar
• Medina-Echeverz J, Fioravanti J, Zabala M, et al. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol 2011;186:807-15
   PubMedGoogle Scholar
• Otano I, Suarez L, Dotor J, et al. Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B. Hepatology 2012;56:474-83
   PubMed Web of Science ®Google Scholar
• Heo J, Breitbach CJ, Moon A, et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma. preclinical and clinical demonstration of combination efficacy. Mol Ther 2011;19:1170-9
   PubMed Web of Science ®Google Scholar
• Wennier S, Li S, McFadden G. Oncolytic virotherapy for pancreatic cancer. Expert Rev Mol Med 2011;13-e18
   Google Scholar
• Pesonen S, Diaconu I, Kangasniemi L, et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res 2012;72:1621-31
   PubMed Web of Science ®Google Scholar
• Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19:2-12
   PubMed Web of Science ®Google Scholar
• Pesonen S, Diaconu I, Cerullo V, et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer 2012;130:1937-47
   PubMed Web of Science ®Google Scholar
• Koski A, Kangasniemi L, Escutenaire S, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010;18:1874-84
   PubMed Web of Science ®Google Scholar
• Cerullo V, Pesonen S, Diaconu I, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010;70:4297-309
   PubMed Web of Science ®Google Scholar
• Hemminki A. Treatment of chemotherapy-refractory cancer in the advanced therapy access program. Mol Ther 2012;20:1654-5
   PubMed Web of Science ®Google Scholar
• Diaconu I, Cerullo V, Hirvinen ML, et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res 2012;72:2327-38
   PubMed Web of Science ®Google Scholar
• Bortolanza S, Bunuales M, Otano I, et al. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in syrian hamsters. Mol Ther 2009;17:614-22
   PubMed Web of Science ®Google Scholar
• Bortolanza S, Alzuguren P, Bunuales M, et al. Human adenovirus replicates in immunocompetent models of pancreatic cancer in syrian hamsters. Hum Gene Ther 2007;18:681-90
   PubMed Web of Science ®Google Scholar
• Thomas MA, Spencer JF, La Regina MC, et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006;66:1270-6
   PubMed Web of Science ®Google Scholar
• Malhotra S, Kim T, Zager J, et al. Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. Surgery 2007;141:520-9
   PubMed Web of Science ®Google Scholar
• Jarnagin WR, Zager JS, Klimstra D, et al. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection. Cancer Gene Ther 2003;10:215-23
   PubMed Web of Science ®Google Scholar
• Stephenson KB, Barra NG, Davies E, et al. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Ther 2012;19:238-46
   PubMed Web of Science ®Google Scholar
• Zhu S, Lee DA, Li S. IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. J Immunol 2010;184:2348-54
   PubMed Web of Science ®Google Scholar
• Chang CJ, Chen YH, Huang KW, et al. Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors. Hepatology 2007;45:746-54
   PubMed Web of Science ®Google Scholar
• Subleski JJ, Hall VL, Back TC, et al. Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver. Cancer Res 2006;66:11005-12
   PubMed Web of Science ®Google Scholar
• He X, Li W, Wang Y, et al. Inhibition of colon tumor growth by IL-15 immunogene therapy. Mol Med Report 2012;5:96-102
   PubMed Web of Science ®Google Scholar
• Bessard A, Sole V, Bouchaud G, et al. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 2009;8:2736-45
   PubMed Web of Science ®Google Scholar
• Yu P, Steel JC, Zhang M, et al. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res 2010;16:6019-28
   PubMed Web of Science ®Google Scholar
• Zhang M, Yao Z, Dubois S, et al. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc Natl Acad Sci USA 2009;106:7513-18
   PubMed Web of Science ®Google Scholar
• Omori R, Eguchi J, Hiroishi K, et al. Effects of interferon-alpha-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors. Cancer Gene Ther 2012;19:637-43
   PubMed Web of Science ®Google Scholar
• Eguchi J, Hiroishi K, Ishii S, Mitamura K. Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing. Cancer Immunol Immunother 2003;52:378-86
   PubMed Web of Science ®Google Scholar
• Eguchi J, Hiroishi K, Ishii S, et al. Interleukin-4 gene transduced tumor cells promote a potent tumor-specific Th1-type response in cooperation with interferon-alpha transduction. Gene Ther 2005;12:733-41
   PubMed Web of Science ®Google Scholar
• Hiroishi K, Tuting T, Tahara H, Lotze MT. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models. Gene Ther 1999;6:1988-94
   PubMed Web of Science ®Google Scholar
• Hansen ML, Woetmann A, Krejsgaard T, et al. IFN-alpha primes T- and NK-cells for. IL-15-mediated signaling and cytotoxicity. Mol Immunol 2011;48:2087-93
   PubMed Web of Science ®Google Scholar
• Boudreau JE, Stephenson KB, Wang F, et al. IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells. Cancer Res 2011;71:2497-506
   PubMed Web of Science ®Google Scholar
• Chew V, Chen J, Lee D, et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 2012;61:427-38
   PubMed Web of Science ®Google Scholar
• Wang P, Yang X, Xu W, et al. Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy. Cancer Immunol Immunother 2010;59:1715-26
   PubMed Web of Science ®Google Scholar
• Narvaiza I, Mazzolini G, Barajas M, et al. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol 2000;164:3112-22
   PubMed Web of Science ®Google Scholar
• Trigatti B, Rigotti A, Krieger M. The role of the high-density lipoprotein receptor SR-BI in cholesterol metabolism. Curr Opin Lipidol 2000;11:123-31
   PubMedGoogle Scholar
• Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117:746-56
   PubMed Web of Science ®Google Scholar
• Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011;13:423-33
   PubMed Web of Science ®Google Scholar
• Bacon BR, Shiffman ML, Mendes F, et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 2009;49:1838-46
   PubMed Web of Science ®Google Scholar
• Fioravanti J, Gonzalez I, Medina-Echeverz J, et al. Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties. Hepatology 2011;53:1864-73
   Google Scholar
• Fioravanti J, Medina-Echeverz J, Ardaiz N, et al. The fusion protein of IFN-alpha and apolipoprotein A-I crosses the blood-brain barrier by a saturable transport mechanism. J Immunol 2012;188:3988-92
   PubMed Web of Science ®Google Scholar
• Parra Guillen ZP, Fioravanti J, et al. Kinetic and dynamic computational model-based characterization of new proteins in mice: Application to interferon alpha linked to apolipoprotein A-I. PLoS One 2012;7:e42100
   PubMed Web of Science ®Google Scholar
• Zhu X, Parks JS. New roles of HDL in inflammation and hematopoiesis. Annu Rev Nutr 2012;32:161-82
   PubMed Web of Science ®Google Scholar
• Ochoa MC, Fioravanti J, Duitman EH, et al. Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy. PLoS One 2012;7:e52370
   Google Scholar
• Ochoa MC, Fioravanti J, Rodriguez I, et al. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. Cancer Res 2013;73:139-49
   Google Scholar
• Pylayeva-Gupta Y, Lee KE, Hajdu CH, et al. Oncogenic kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 2012;21:836-47
   PubMed Web of Science ®Google Scholar
• Bayne LJ, Beatty GL, Jhala N, et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012;21:822-35
   PubMed Web of Science ®Google Scholar
• Tysome JR, Li X, Wang S, et al. A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity. Clin Cancer Res 2012;18:6679-89
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer–what clinicians need to know. Nat Rev Clin Oncol 2011;8:577-85
   PubMed Web of Science ®Google Scholar
• Perna SK, De Angelis B, Pagliara D, et al. Interleukin 15 provides relief to cytotoxic T lymphocytes from regulatory T cell-mediated inhibition: implications for adoptive T-cell based therapies of lymphoma. Clin Cancer Res 2012;1078-0432
   Google Scholar
• Pegram HJ, Lee JC, Hayman EG, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012;119:4133-41
   PubMed Web of Science ®Google Scholar